Otros idiomas Regulus Therapeutics Inc.

Acciones

RGLS

US75915K3095

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 02/05/2024			Varia. Cinco días.	Varia. 1 de enero.
2,67 ^USD	+6,37 %		+17,62 %	+108,59 %

21/03	Regulus Therapeutics Inc. informa de los resultados del ejercicio finalizado el 31 de diciembre de 2023	CI
21/03	Regulus Therapeutics Inc. informa de los resultados del cuarto trimestre finalizado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series	30/04
Regulus Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Regulus: Q4 Earnings Snapshot	21/03
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates	21/03
Regulus Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
Emerging Companies: Key Developments and Investment Insights RGLS, INBS, VTAK, DYAI, TCBP	14/03
Regulus Therapeutics Inc. announced that it has received $100.000267 million in funding from a group of investors	14/03
Top Midday Gainers	12/03
Regulus Therapeutics Reports 'Positive' Data From Second Cohort of Kidney Disease Trial -- Shares Rise	12/03
Consumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-Bell	12/03
Top Premarket Gainers	12/03
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity	12/03
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	12/03
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in Its Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	12/03
Regulus Therapeutics Inc. announced that it expects to receive $100.000267 million in funding from a group of investors	11/03
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)	02/01
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease	02/01
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference	22/11
Regulus Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Regulus: Q3 Earnings Snapshot	09/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Regulus Therapeutics Inc.

Acciones

RGLS

US75915K3095

Otros idiomas

Filtros